Glad to hear it, Dave. Perhaps we're just beginnin
Post# of 30028
This is certainly a much different business model than the other biotech companies out there, but one that appears to have the potential to be highly lucrative for the company and its shareholders. This is most likely what attracted the talent that has joined the company. They see the future of this approach, even if most investors are taking longer to come around.